- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01888549
Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Gangnam Severance Hospita
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
ages of 18 and 70 years had chronic cough of >8 weeks in duration
Exclusion Criteria:
1. abnormal chest X ray, PNS view 2. previous surgical or endoscopic antireflux procedure 3. previous aerodigestive malignancy or Barrett's oesophagus 4. current smokers or ex-smok-ers (defined as those who quit smoking <3 months prior to study enrolment or those who have quit, but have a 20 pack year smoking history) 5. Malignancy History (lung cancer, esophageal cancer etc.) 6. upper respiratory infection within 8 weeks of study enrolment 7. currently using a PPI, H2 blocker, beta-blocker, angiotensin-converting enzyme inhibitor, corticosteroid, methylxanthine, inhaled beta-agonist, anti-inflammatory agent or anticholinesterase drug at time of enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: arm1-High dose PPI
|
:40mg, po(per oral) 2times.day,
8weeks
|
|
Active Comparator: arm2-standard dose PPI
|
: 40mg, po(per oral) 1times.day,
8weeks
|
|
Placebo Comparator: arm3-placebo
Esomeprazole placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in LCQ score and cough VAS, comparing PPI-treated group to placebo
Time Frame: change in LCQ score after 4 weeks and 8 weeks
|
change in LCQ score after 4 weeks and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in LCQ score and cough VAS, comparing PPI-treated group to placebo
Time Frame: change in cough VAS after 4weeks and 8 weeks
|
change in cough VAS after 4weeks and 8 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Signs and Symptoms, Respiratory
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophagitis
- Peptic Ulcer
- Duodenal Diseases
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Cough
Other Study ID Numbers
- 3-2011-0103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Cough Caused by Gastroesophageal Reflux
-
University Hospital OstravaNot yet recruitingDysphagia | Laryngopharyngeal Reflux | Chronic Cough | Extraesophageal RefluxCzechia
-
University Hospital OstravaRecruitingAsthma | Allergy | Laryngopharyngeal Reflux | Chronic Cough | Extraesophageal RefluxCzechia
-
Mayo ClinicUniversity of ManchesterCompletedGastroesophageal Reflux Disease | Chronic Cough | Broncho-hyperreactivityUnited States
-
NYU Langone HealthCompletedChronic Cough (CC) | Gastroesophageal Reflux (GER)United States
-
Mayo ClinicRecruitingRefractory Chronic CoughUnited States
-
Cough Monitoring Medical SolutionsUniversidade Nova de LisboaRecruitingChronic Obstructive Pulmonary Disease | Cough | Asthma | Gastro Esophageal Reflux | Idiopathic Pulmonary Fibrosis | Coughing | Cough Severity | Cough FrequencyPortugal
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingCough | Laryngopharyngeal Reflux | Dysphonia | Reflux | Throat ClearingUnited States
-
Moscow City Hospital named after A.K. EramishantsevPirogov Russian National Research Medical University; Vishnevsky Center of...CompletedVaricose Veins | Venous Reflux | Chronic Venous Insufficiency (CVI) | Chronic Venous Disorder | Great Saphenous Vein (GSV) With Venous Reflux DiseaseRussian Federation
-
Kazakh Medical University of Continuing EducationAsfendiyarov Kazakh National Medical UniversityCompletedGastro Esophageal Reflux Disease | Laryngopharyngitis Chronic | Laryngopharyngeal Reflux SymptomsKazakhstan
-
AstraZenecaCompletedEsomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis PatientsChronic Gastritis | Non Erosive Reflux DiseaseChina
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States